
Opinion|Videos|December 8, 2023
Evaluating the Impact of Elacestrant Use in Clinical Practice for Patients With ER+/HER2-Metastasized Breast Cancer
Author(s)Joyce O'Shaughnessy, MD
Identifying the impact of elacestrant in clinical practice for patients with ER+/HER2- metastatic breast cancer.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5










































